Ondine Biomedical
Ondine reports 40% reduction in surgical-site infections in phase 3 trial
September 9, 2026Ondine Biomedical, nasal photodisinfection technology, phase 3 trial, surgical-site infections
Ondine Biomedical has reported a 40% relative reduction in 30-day surgical-site infections (SSIs) in a 5,188-patient phase 3 trial of …
